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Abstract 
Purpose of review: Peripheral T-cell lymphomas (PTCL) represent diverse and 
aggressive malignancies, with few recent therapeutic improvements. Recent high-
throughput genomic studies have revealed the complex mutational landscape of 
these rare diseases. These novel findings provide the grounds to a more 
comprehensive classification of these diseases, reflected in the 2017 WHO 
classification. 
 
Recent findings: Our review is focused on selected PTCL entities. 
Angioimmunoblastic T-cell lymphoma and other lymphomas derived from T follicular 
helper cells feature a rather homogeneous mutational landscape. These neoplasms 
recapitulate a multi-step oncogenic process associating epigenetic deregulation, and 
second hit mutations affecting the T-cell receptor signaling pathway. This model 
inferred from comprehensive analyses of patients samples was confirmed in mouse 
models. Amongst ALK-negative anaplastic large-cell lymphomas, translocation-
associated subsets are found in both systemic and cutaneous types, and the newly 
described breast implant-associated type is usually indolent. Extranodal lymphomas 
of the innate immune system also harbor a combination of mutations affecting 
different classes of epigenetic modifyers, and mutation-induced activation of the 
Janus Kinase/signal transduction and activator of transcription pathway. 
 
Summary: Understanding of PTCL pathogenesis has substantially improved, and 
oncogenic events have been identified. The current challenge is to mount efficient 
therapeutic strategies targeting these aberrations to improve patients outcome. 
Keywords: next generation sequencing, follicular helper T-cell lymphoma, 
epigenetics, anaplastic large-cell lymphoma, extranodal, signaling pathways 
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Introduction 
 
Peripheral T-cell lymphomas (PTCLs) represent less than 15% of all non-Hodgkin 
lymphomas worldwide. Recent high-throughput molecular and genomic profiling 
studies have generated many discoveries that significantly advanced our 
understanding of the pathogenesis and pathobiology of these diseases. The genetic 
alterations in PTCL target multiple pathways. Highly recurrent mutations occur in 
different classes of epigenetic modifiers (1-5*), in T-cell receptor and co-receptors 
signaling pathways (6*, 7), and in components or regulators of the Janus kinase 
(JAK)/signal transducer and activator of transcription (STAT) pathway. There is 
established or presumed evidence that the resulting functional deregulations 
represent pathogenic mechanisms contributing to induce or maintain some attributes 
of the malignant phenotype (8). Although a few variants are characteristic of certain 
entities, for example RHOAG17V, no novel disease-defining mutation has been found, 
there is major overlap in the mutational landscapes of different entities, and ALK-
positive anaplastic large-cell lymphoma (ALCL) essentially remains the only PTCL 
defined by a specific genomic rearrangement.  
Some of these new molecular findings have been incorporated into the revised 
edition of the World Health Organization classification (2017) as they refine 
classification and diagnostic criteria (9). The currently recognized PTCL entities, 
grouped according to their clinical presentation and localization, are listed in Table 1 
(10), (9). This review will address more recent advances gained in the knowledge of 
selected T-cell lymphoma entities.  
Angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of T 
follicular helper (TFH) derivation  
Besides the constellation of histological and clinico-biological features characteristic 
of the disease, AITL definition also refers to its TFH derivation (11). The mutational 
landscape of AITL comprises frequent mutations in three genes directly or indirectly 
involved in the regulation of DNA methylation/hydroxymethylation. Sensitive 
sequencing methods detect TET2 DNMT3A and IDH2 mutations in about 80% (12-
14),  20-30% (12, 15, 16) and 20-30% of the cases (17) , respectively. TET2 is an α-
ketoglutarate-dependent dioxygenase, involved in the successive oxidation of 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) to 5-formylmethylcytosine 
and 5-carboxymethylcytosine, resulting in the demethylation of 5-cytosine, through 
the thymine DNA glycosylase-mediated base excision system (18). Thus, TET2 plays 
an important role in active cytosine demethylation. DNMT3A is a de novo DNA 
methyltransferase, involved in the transformation of 5-cytosine to 5mC (19). 
Mutations in TET2 and DNMT3A are loss-of-function and distributed along the coding 
sequences of the genes, with few hotspots, such as the dominant-negative 
DNMT3AR882X mutant (20). IDH2 mutations occur specifically at the R172 residue 
(16, 21), and confer a neoenzymatic activity producing D-2 hydroxyglutarate (22). 
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This metabolite, physiologically present at very low levels, inhibits numerous α-
ketoglutarate-dependent dioxygenases, including TET proteins or histone 
demethylases (23). While IDH1/2 and TET2 mutations in acute myeloid leukemia are 
mutually exclusive, both resulting in a specific methylation profile (24), for unknown 
reasons they frequently coexist in AITL. Although TET2, DNMT3A and IDH2 
mutations have in principle opposite effect on cytosine methylation levels, they all 
individually result in decreased 5hmC levels. Interestingly, compared to normal TFH 
cells, 5hmC levels are decreased in AITL, and more generally in PTCL, regardless of 
mutations, suggesting that epigenetic deregulation is a general event during the 
lymphomagenesis (21). However, the functional consequences of these changes in 
cytosine methylation/hydroxymethylation are yet poorly understood and warrant 
further comprehensive studies.  
A missense mutation encoding the pG17V substitution in RHOA GTPase is 
detected in 50-70% AITL patients  (6*, 13, 14, 25). RHOAG17V lacks the ability to bind 
GTP, which results in defective RHOA signaling, with an inhibitory dominant-negative 
effect on RHOA downstream targets, contrasting with the increased proliferation and 
invasiveness observed in RHOAG17V-mutated cells (6*, 13, 14). A recent study solved 
this paradox in showing that RHOAG17V, but not the wild-type form of the GTPase, 
binds and phosphorylates VAV1, resulting in activation of Nuclear Factor of Activated 
T-cells (NFAT) and subsequently in T-cell receptor (TCR) signaling (26). In line with 
this concept, RHOA mutations and VAV1 abnormalities are mutually exclusive (6*, 
26). In addition, various activating mutations, distributed along the TCR and co-
stimulation signaling pathways are detected in up to 50% patients and were found to 
correlate with cell activation and proliferation gene expression signatures (6*). The 
most frequented mutated genes are PLCG1 (27), CD28 (28) and PIK3 components 
(6*). In addition, fusions involving CD28 and CTLA or CD28 and ICOS have been 
detected in AITL (7). Initially reported as highly recurrent events (29), these fusions 
are in fact detected in less than 10% of patients (7, 30). ICOS-CD28 fusions are 
more prevalent and likely result in an enhanced CD28 signal (7). CTLA4-CD28 
fusions are less common and have the unique feature to link extracellular CTLA4 
engagement to an activating signal through CD28 intracellular moiety. Anti-CTLA4 
antibody ipilimumab can block this signal and clinical efficacy was reported in one 
case (31).  
An interesting finding in AITL is that TET2 and DNMT3A mutations can be 
detected not only in neoplastic T cells, but also in CD34-derived colonies (32), in 
CD34+ cells (17) and in B cells isolated from AITL biopsies (33*, 34). Furthermore, 
variant allele frequencies of TET2 and DNMT3A are higher than those of RHOA or 
IDH2. This supports that the former two mutations can occur in a hematopoietic 
progenitor or stem cell. Conversely, RHOA (33*) and IDH2 (33*, 35) mutations are 
restricted to tumor cells, indicating that they are likely a second hit in an oncogenic 
multistep process (Figure 1). Furthermore, since TET2 or DNMMT3A mutations can 
be detected at significant levels in the blood of elderly individuals, reflecting at least 
partly a clonal hematopoiesis (36-39), they are not sufficient by themselves to induce 
a T-cell neoplasm. 
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Several mouse models further support the hypothesis of a multistep oncogenic 
process. The combination of TET2 inactivation and DNMT3 mutation can induce 
various hematological diseases including PTCL, only after transplantation and with a 
low penetrance (40), whereas TET2 inactivation and RHOAG17V altogether result in 
the development of an AITL-like disease with a much higher penetrance. The first 
model used engineered TET2-deficient T cells, transfected with RHOAG17V construct. 
Recipient mice developed AITL-like disease, where decrease in FOXO1 appeared 
essential for tumor cells survival (41*). Two transgenic mouse models with 
expression of RHOAG17V in the T-cell compartment demonstrated the role of 
RHOAG17V in T-cell development, TFH differentiation, and in inducing autoimmunity. 
However, additional TET2 inactivation is required for lymphoma development (42**, 
43). It is expected that these mouse models will facilitate testing of novel therapies. 
Of note, mouse TFH lymphomas are dependent on ICOS/PIK3/MTOR signaling 
(42**, 43), which may represent innovative therapeutic targets.  
Recent epidemiological data indicate that AITL prevalence is much higher than 
previously reported (44, 45). Moreover, expression of a TFH immunophenotype was 
also found in the very rare follicular variant of PTCL (F-PTCL), and about 20-30% of 
PTCL previously classified as “not otherwise specified” (TFH-PTCL) (3, 46, 47). This 
raised the question whether AITL, F-PTCL and TFH-PTCL represent morphological 
variants of the same disease or distinct diseases with similar phenotype. A recent 
study showed that these lymphomas also have comparable clinical presenting 
features including auto-immunity, and outcome, and similar genomic imbalances and 
mutational profiles. A same frequency of TET2, DNMT3A and RHOA mutations was 
found in AITL, F-PTCL and TFH-PTCL (13, 48*), only IDH2 mutations being more 
frequently present in AITL (15, 16). This suggests a common oncogenic process in 
these lymphomas, which is reflected in the 2017 classification by grouping them as 
related diseases (Table 1). 
 
Anaplastic large cell lymphomas (ALCLs) 
 
ALCLs include four entities having in common a large-cell anaplastic morphology, 
strong CD30 expression, and frequent phospho-STAT3 activation: anaplastic 
lymphoma kinase (ALK)-positive and ALK-negative ALCL, which altogether represent 
about 15-20% of non-cutaneous PTCLs, primary cutaneous ALCL (pcALCL) and the 
recently characterized provisional entity, breast implant-associated ALCL (BI-ALCL) 
(9). 
In ALK-positive ALCL, ALK expression results from the fusion of the ALK gene 
to various partners, most commonly NPM1 (nucleophosmin). It occurs mainly in 
children or young adults, may involve lymph nodes and/or various extranodal sites 
and has an overall excellent prognosis. Recently, an increasing number of cases of 
cutaneous ALCL positive for ALK expression have been reported both in children and 
aduls, that presented as isolated cutaneous lesions without systemic involvement, 
and in most instances did not disseminate outside the skin and had an excellent 
outcome, arguing against the contention that ALK expression in ALCL is usually the 
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indication of a systemic disease, and suggesting that ALK rearrangements represent 
that pathogenic event in a small subset of pcALCLs (49)   
ALK-negative ALCL tends to occur in older individuals and encompasses 
genetic heterogeneity, and two separate studies have now shown the clinical 
correlations to the genetic subgroups. Those with rearrangement of 
the DUSP22 locus @ 6p25 (about one third of the cases) have a good outcome 
similar to that of ALK-positive ALCLs; conversely, the small subset of ALK-negative 
ALCLs with TP53 rearrangements has a very poor outcome (50).  
pcALCL is an ALK-negative ALCL within the spectrum of primary cutaneous 
CD30+ lymphoproliferative disorders (which also encompasses various types of 
lymphomatoid papulosis), and usually portends a good prognosis. Recent findings, 
have shown partial overlap in the pathogenic mechanisms of primary cutaneous and 
systemic ALK-negative ALCLs. Nevertheless, the reasons underlying the distinctive 
clinical features of pc versus systemic ALCL remain unknown. About one third of 
pcALCL carry DUSP22 rearrangements (51) and some of these feature a biphasic 
pattern (dermal infiltrate of medium-to-large cells, and epidermotrophism by small 
atypical lymphocytes) similar to that seen in uncommon DUSP22-rearranged 
lymphomatoid papulosis (52) Two cases of pcALCL with TP53 rearrangements were 
reported with an aggressive clinical course but experience is limited to draw definitive 
conclusions. (53) Translocations involving the TYK2 tyrosine kinase have been found 
in a small subset of pcALCL and lymphomatoid papuloses, and also in systemic ALK-
negative cases (54, 55). The best characterized translocation encodes a NMP1-
TYK2 fusion protein that induces TYK2 activation, STAT1/3/5 activation, but other 
gene partners in variant translocations are not known. Enhancer of zeste homolog 2 
(EZH2), a catalytic unit with histone methyltransferase activity, is consistently 
overexpressed in pcALCL neoplastic cells, and showed how mechanistically 
epigenetic silencing by EZH2 deregulation might promote tumor progression, by 
inhibiting tumor cell apoptosis and by derepressing CXCL10 and incrasing the influx 
of effector T cells to the lesions (56). 
BI-ALCL is a new provisional PTCL entity (9) with morphological and 
immunophenotypical features indistinguishable from those of other ALK-negative 
ALCL, and a specific clinical presentation, adjacent to a breast implant. Most cases 
confined to the periprosthetic effusion and capsule (seroma or « in situ » lymphoma) 
have excellent outcomes, and a minority of patients present with a breast tumor 
mass, which is an adverse prognostic factor (57, 58).  
A recent population-based case-control study from the Netherlands concluded to a 
very high (over 400) relative risk for BI-ALCL in women with breast implants, but to a 
small absolute cumulative risk with about one of 7000 women with breast implants 
would develop BI-ALCL before the age of 75 (59). The pathogenesis of BI-ALCL 
remains elusive. It has been suggested that a local inflammatory response elicited by 
silicone-derived products or bacteria adherent to the surface of the prosthesis, might 
play a role. Genetically, while cell lines derived from BI-ALCL effusions have unstable 
and complex karyotypes (60), the few primary lymphoma samples examined so far 
show no or few alterations. The recurrent translocations found in other ALK-negative 
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ALCL have not been found (57, 61). Conversely, similar to other ALK-negative 
ALCLs, activation of STAT3 is common and mutations of JAK1 or STAT3 have been 
reported in individual case reports and small series (61-64)*. 
 
Lymphomas of the innate immune system  
 
Extranodal non-cutaneous PTCL derive from cytotoxic cells of the innate immune 
system. Besides EBV-associated extranodal NK/T-cell lymphoma (ENKTCL) which is 
not uncommon in Western countries and relatively frequent in Asia, hepatosplenic T-
cell lymphoma (HSTL), enteropathy-associated T-cell lymphoma (EATL) and 
monomorphic epitheliotropic T-cell lymphoma (MEITL)  are rare or very rare 
diseases. Mutation-induced activation of the JAK-STAT pathway (usually mutually 
exclusive JAK1, JAK3, STAT3, STAT5B mutations) is a hallmark pathogenic 
mechanism common to these extranodal PTCLs. Interstingly, addiction to 
JAKs/STATs, irrespective of mutations, may be antagonized by pharmacological 
inhibitors (65). 
There is a wide spectrum of EBV positive NK/T-cell lymphoproliferations/ 
lymphomas in adults and children, which are clinically heterogeneous (leukemic, 
extranodal lesions, nodal involvement, cutaneous) with more or less indolent or 
aggressive behavior (Table 1). ENKTCL is an angiocentric and angiodestructive 
lymphoma of NK or less commonly T-cell derivation. In ENKTCL, mutations in JAK3, 
STAT3 and STAT5b often co-occur with epigenetic mutations (BCOR, others), and 
mutations in DDX3X which encodes a RNA helicase and in TP53 (66). A genome-
wide association study identified polymorphism in HLA-DP, rs9277378, as a risk 
factor for ENKTCL, reinforcing the role of HLA-DP presentation in oncogenesis (67).  
Cases with upper aerodigestive presentation have a better outcome than those 
presenting elsewhere. Exclusively nodal presentation is uncommon and associated 
to a shorter survival, and interestingly gene expression and copy number alterations 
in nodal versus extranodal cases have been found different (68). A subset of 
ENKTCL may develop a hemophagocytic syndrome (HPS), and a genetic basis - a 
specific mutation in ECSIT, an immune regulatory gene - was recently discovered for 
this often fatal hyperinflammatory complication. Functional studies nicely 
demonstrated that ECSIT-V140A variant activates NF-kappaB signaling and induces 
proinflammatory cytokine production, and the possibility of specific pharmacologic 
inhibition (69*). Aggressive NK leukemia harbors a mutational pattern similar to 
ENKTCL, with mutations in DDX3X, STAT3 and in the RAS/MAPK pathway (70).  
HSTL and MEITL are rare, highly aggressive and essentially incurable 
diseases, most commonly derived from gamma-delta T cells, the former involving the 
spleen and liver with a sinusoidal pattern in young individuals, the latter forming 
tumors derived from intestinal intraepithelial lymphocytes in individuals with no 
history of celiac disease or enteropathy (71). Both entities frequently feature 
JAK/STAT pathway activation, most often due to STAT5B mutations (4*, 72, 73). In 
addition, recent works have highlighted the role of epigenetic disturbances in these 
entities. Whole exome sequencing analysis of MEITL led to the discovery of highly 
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recurrent alterations of SETD2 encoding a non-redundant H3K36-specific 
trimethyltransferase in 14/15 cases (93%). SETD2 alterations were often biallelic, 
mainly by loss-of-function mutations and/or 3p21.31 deletion. SETD2 is also the top 
mutated gene in HSTL (about one third of the cases) (4*). In a T cell–specific SETD2 
knockout mouse model, mice manifested an expansion of γδ T cells, indicating novel 
roles for SETD2 in T-cell development and lymphomagenesis (5). Besides T-cell 
lymphomas, mucosal lymphoproliferations of clonal T or NK cells with an indolent 
behavior were recently described in the digestive tract (74). The gastrointestinal 
indolent T-cell lymphoproliferative disorders encompassesheterogeneous 
immunophenotypes (CD4+, CD8+, CD4-CD8- or CD4+CD6+) and CD4+ cases may 
progress to a malignant T-cell lymphoma (75). Recently, STAT3-JAK2 fusions were 
discovered in 4/5 CD4+ cases, while none of the other five cases with CD8+ or 
CD4+CD8+ phenotypes harbored the fusion, which might be targeted by JAK2 
inhibitors (76*).  
 
Conclusion 
High-throughput sequencing analyses of most PTCL entities have substantially 
improved our understanding of PTCL pathogenesis, and oncogenic events have 
been identified in most PTCL entities. The current challenge is to mount efficient 
therapeutic strategies targeting these aberrations to improve patients outcome.
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Key points:  
 
 Mutational profiling of the many PTCL entities has revealed diverse mutational 
landscapes which are advancing our understanding of the pathogenesis of 
these rare and aggressive diseases 
 
 The highly prevalent nodal lymphomas of follicular helper T-cell origin are 
characterized by a multistep oncogenetic pathway involving epigenetic 
deregulation related to TET2, DNMT3 or IDH2 mutations, and gain-of-function 
mutations affecting genes related to T-cell receptor signaling pathway 
 
 While PTCL are usually aggressive disease, several indolent entities are 
recognized, including CD30+ anaplastic large-cell lymphoma associated to 
breast implants, and indolent clonal proliferations of mature T cells in the 
gastrointestinal tract 
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Figure Legend 
 
Figure 1: Model of TFH PTCL oncogenesis.  
TET2 and DNMT3A mutations, disrupting the epigenetic regulation, occur in 
hematopoietic progenitors whereas RHOAG17V and other mutations affecting cell 
signaling components occur in TFH cells, as second hit events. Note that IDH2 
mutation co-exist with TET2 mutation and is restricted to tumor cells.  
CLP, common lymphoid progenitor; CMP, common myeloid progenitor; HSC, 
hematopoietic stem cell; HPC, hematopoietic progenitor cell. 
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Table 1: 2017 WHO classification of mature T-cell neoplasms (adapted from (9),  
with summary of changes and novelties in comparison to the previous edition 
(10) (* designates provisional entities) 
 
Mature T-cell neoplasms Changes and novelties 
Disseminated/leukemic  
T-cell prolymphocytic leukemia Mutation-induced activation of the 
JAK/STAT pathway in a large proportion 
of the cases, in addition to the 
pathognomonic translocations involving 
TCL1A/B or MTCP1 
T-cell large granular lymphocytic 
leukemia 
Genetic heterogeneity (STAT3 
mutations in one third of the cases, 
STAT5B uncommon) correlates with 
clinical features (STAT5B mutations in 
more aggressive diseases) 
Chronic lymphoproliferative disorder of 
NK cells* 
Mutational profile similar to that of T-cell 
large granular lymphocyte leukemia 
Aggressive NK-cell leukemia  
Systemic EBV-positive T-cell lymphoma 
of childhood* 
Designation changed from 
“lymphoproliferative disorder” to 
“lymphoma” due to the aggressive 
fulminant clinical course, usually 
complicagted by haemophagocytic 
syndrome 
Chronic active EBV infection of T- and 
NK-cell type, systemic form 
Often monoclonal, immunophenotype is 
predominantly CD4+, clinical course 
variable, haemophagocytic syndrome 
may occur 
Adult T-cell leukemia/lymphoma Recent advances in genomic 
characterization 
Nodal  
Angioimmunoblastic T-cell lymphoma Defined as a lymphoma of mature 
follicular helper T cells (TFH), 
considered as an entity within the 
spectrum of nodal lymphomas of 
follicular helper T cell origin (an 
umbrella category which also 
encompasses follicular T-cell lymphoma 
and nodal peripheral T-cell lymphoma 
with T follicular helper phenotype) 
Follicular T-cell lymphoma Formerly classified as a variant 
peripheral T-cell lymphoma, not 
Manuscript (incl Abstract and Keywords)
  
otherwise specified; now classified as 
an entity in the spectrum of nodal TFH 
lymphomas  
Nodal peripheral T-cell lymphoma with 
T follicular helper phenotype 
Formerly not identified as an entity and 
considered as of peripheral T-cell 
lymphoma, not otherwise specified.  
Anaplastic large cell lymphoma, ALK-
positive 
 
Anaplastic large cell lymphoma, ALK-
negative 
Formerly provisional, now promoted to a 
definitive entity. Genetic subsets 
(DUSP22 rearrangements, TP63 
translocations) with distinctive 
pathological features and clinical 
outcome. 
Peripheral T-cell lymphoma, not 
otherwise specified 
Requires the exclusion of a TFH 
immunophenotype. 
Molecular subsets defined on the basis 
of gene expression signatures and 
expression of Th1 versus Th2 
transcription factors, may be clinically 
relevant but are not yet advocated to be 
assessed in diagnostic practice. 
Extranodal  
Extranodal NK/T-cell lymphoma, nasal 
type 
 
Enteropathy-associated T-cell 
lymphoma 
Formerly type I enteropathy-associated 
T-cell lymphoma, usually associated to 
celiac disease 
Monomorphic epitheliotropic intestinal 
T-cell lymphoma 
Formerly type II enteropathy-associated 
T-cell lymphoma; considered as a 
separate entity due to lack of 
association to celiac disease and 
distinctive pathological features; the 
designation “monomorphic 
epitheliotropic” refers to characteristic 
morphological features of this 
neoplasm. 
Indolent T-cell lymphoproliferative 
disorder of the gastro-intestinal tract* 
New provisional entity to designate 
clonal but indolent lymphoproliferative 
disorders of the gastrointestinal tract; a 
variety of immunophenotypes may be 
encountered; some cases may progress 
to overt lymphoma 
  
Hepatosplenic T-cell lymphoma  
Subcutaneous panniculitis-like T-cell 
lymphoma 
Limited to cases of alpha-beta 
derivation; may be associated to 
autoimmune disorders; good prognosis 
Breast implant-associated anaplastic 
large cell lymphoma* 
New provisional entity; similar to ALK-
negative anaplastic large cell 
lymphoma. 
Cutaneous  
Mycosis fungoides  
Sezary syndrome  
Lymphomatoid papulosis 
     
New types of lymphomatoid papulosis 
recognized: strongly epidermotropic, 
angiocentric/angiodestructive, and 
those associated to a DUSP22 
rearrangement histologically mimicking 
transformed mycosis fungoides. 
Primary cutaneous anaplastic large cell 
lymphoma 
 
Primary cutaneous γδ T-cell lymphoma 
 
Other entities that may comprise a 
subset of cases with a γδ TCR 
phenotype, must be excluded (for 
example extranodal NK/T-cell 
lymphoma, mycosis fungoides, 
lymphomatoid papulosis) 
Primary cutaneous CD8+ aggressive 
epidermotropic cytotoxic T-cell 
lymphoma* 
Must be distinguished from type D 
lymphomatoid papulosis 
Primary cutaneous acral CD8+ T-cell 
lymphoma* 
New provisional entity to designate 
indolent cutaneous CD8+ 
lymphoproliferations, as described 
originally in the ear 
Primary cutaneous CD4+ small/medium 
T-cell lymphoproliferative disorder* 
Designation changed from “lymphoma” 
to “lymphoproliferative disorder” due to 
usually indolent clinical features 
Hydroa vacciniforme-like 
lymphoproliferative disorder 
Cutaneous form of chronic active EBV 
infection 
Severe mosquito bite allergy  
 

